Drug Trial Radar · NCT07193147
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 20, 2025
Primary completion
Jul 14, 2026
Study completion Nov 4, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.
Conditions
- Diabetes
Interventions
GZR4Drug
GZR4 s.c., single-dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: through study completion, an average of 29 days
- AUC0-lastTime frame: through study completion, an average of 29 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Linyi, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.